COURT-RULING ·Filed Jul 20, 2026

SUPN

SUPERNUS PHARMACEUTICALS, INC.
NEUTRAL
Impact 3/10
Horizondays Processed2mo ago CourtView Ruling on CourtListener
Court ruling (district)
Actionable Insight • Neutral

Monitor for the full opinion text or subsequent SEC filings (8-K Item 2.03 or 8.01) that may disclose the ruling's outcome and any material financial exposure. Without the opinion, no trading action is warranted.

DirectionNeutral
Confidencelow
Horizondays
Latest settled — T+20d
SUPN ▲ +1.79% at T+20d
NEUTRAL call ✓ call won +1.79% · α vs SPY -2.33% · entry $47.42 → $48.27
Next anchor: T+60d in 10d
Latest observation: T+51 -2.50% FF3 residual α
Entry anchored
Jul 17, 03:59 PM ET
via exchange tick
T+1d
+0.95%
call +0.95% · α +0.11%
$47.87
settled 2mo ago
T+5d
-2.57%
call -2.57% · α -2.15%
$46.20
settled 2mo ago
T+20d
+1.79%
call +1.79% · α -2.33%
$48.27
settled 7w ago
T+60d
—
call — · α —
—
in 10d

Price Chart

Loading chart...

Executive Summary

A Delaware Superior Court ruling in US Worldmeds Partners, LLC v. Supernus Pharmaceuticals, Inc. was filed on July 20, 2026, but the full opinion text is unavailable. The case involves a contract dispute with a counterparty, but without the ruling's reasoning or outcome, the material impact on SUPN cannot be assessed. This is a low-confidence analysis based on metadata only.

Court Ruling Details

Ruling Date
Jul 20, 2026
Court
Delaware Superior Court
Court Level
District
Case Type
contract
Ruling Type
other
Will It Be Appealed?
N/A (final)
Precedent Risk
LOW

Key Facts

  • A Delaware Superior Court ruling was issued on July 20, 2026 in a case between US Worldmeds Partners, LLC and Supernus Pharmaceuticals, Inc.
  • The full opinion text was unavailable for analysis, preventing assessment of the ruling's direction or financial exposure.
  • The case is at the district level (Delaware Superior Court) and involves a contract dispute.

Financial Impact

Not determinable — opinion text unavailable

Risk Factors

  • The ruling could impose material damages or injunctive relief on SUPN, but the magnitude is unknown without the opinion text.
  • The historical calibration shows SUPN reports have underperformed at T+20, suggesting caution on directional bets based on this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-6d231b94cd-SUPN
20 reports for SUPN
Performance horizon
75% Hit rate 6 of 8 directional calls best @ T+1▲ +8.46%Aug 3, 2026
Filters
Rows
Reports for SUPN — sortable, filterable
TypeNow
Sep 11, 2026
20d ago
DEFM14A
MIXED ★ 7/10
$41.49 $42.78▲ +3.11%▲ +3.00%$42.60 (+2.68%)
Aug 3, 2026
8w ago
DEFA14A / 425
BULLISH ★ 7/10
$43.25 $46.88▲ +8.39%▲ +8.49%$42.60 (−1.50%)
Aug 3, 2026
8w ago
8-K
BULLISH ★ 7/10
$43.25 $46.88▲ +8.39%▲ +8.49%$42.60 (−1.50%)
Aug 3, 2026
8w ago
DEFA14A / 425
BULLISH ★ 8/10
$46.00 $47.07▲ +2.33%▲ +0.30%$42.60 (−7.39%)
Aug 3, 2026
8w ago
8-K
BULLISH ★ 7/10
$46.00 $47.07▲ +2.33%▲ +0.30%$42.60 (−7.39%)
Aug 3, 2026
8w ago
8-K
MIXED ★ 7/10
$46.00 $47.07▲ +2.33%▲ +0.30%$42.60 (−7.39%)
Aug 3, 2026
8w ago
DEFA14A / 425 / 8-K
BULLISH ★ 8/10
$46.00 $47.07▲ +2.33%▲ +0.30%$42.60 (−7.39%)
Jul 22, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$47.19 $45.61▼ −3.35%▼ −3.82%$42.60 (−9.73%)
Jul 22, 2026
10w ago
Press Release
NEUTRAL ★ 2/10
$47.19 $45.61▼ −3.35%▼ −3.82%$42.60 (−9.73%)
Jul 20, 2026
10w ago
Court Ruling
NEUTRAL ★ 3/10
$47.42 $46.20▼ −2.57%▼ −2.15%$42.60 (−10.16%)
Showing 10 of 20

US Market Status

Market Open — Closes in 51m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access